Shawn P. Griffin
Biography
Shawn P. Griffin, PharmD, BCOP, is Assistant to the Dean for PharmD Student Professional Development and Health Sciences Associate Clinical Professor in the Department of Clinical Pharmacy Practice at the UC Irvine School of Pharmacy & Pharmaceutical Sciences. He also serves as a Pharmacist Specialist in the Hematology/Hematopoietic Stem Cell Transplantation and Cellular Therapy Program at UCI Health. His clinical and research work focuses on hematologic malignancies and hematopoietic stem cell transplantation, with particular interests in treatment outcomes for underserved populations, pharmacokinetics of conditioning regimens, and the optimization of oncology pharmacy practice.
Griffin has led and contributed to research funded by the Hematology/Oncology Pharmacy Association (HOPA) and the American Cancer Society, including studies examining pegaspargase-induced liver injury in Hispanic patients with acute lymphoblastic leukemia and pharmacokinetic optimization of melphalan-based conditioning regimens. He serves as Vice-Chair of the Board of the California Chapter of the Oncology Pharmacy Network and is a member of the Hematology Research & Outcomes (HERO) Consortium. Griffin is a past recipient of the HOPA Volunteer of the Year Award and the HOPA Pharmacy Practice Research Article of the Year Award.
Griffin completed his Doctor of Pharmacy with Distinction at the University of North Carolina Eshelman School of Pharmacy, followed by an ASHP-accredited PGY1 residency at UF Health Shands Hospital and a PGY2 Hematology/Oncology residency at UF Health Shands Cancer Hospital. He holds board certification as an oncology pharmacist (BCOP) and has been an invited reviewer for numerous peer-reviewed journals, including the Journal of Oncology Pharmacy Practice, the European Journal of Haematology, and JCO Oncology Practice.
Return to topEducation
- PharmD, University of North Carolina Eshelman School of Pharmacy, 2014
- BS in Biology, Boston College, 2010
Distinctions
- Hematology/Oncology Pharmacy Association Pharmacy Practice Research Article of the Year, 2026
- Hematology/Oncology Pharmacy Association Volunteer of the Year, 2024
- ACCP Hematology/Oncology PRN Emerging Member, 2022
- UC Irvine Chao Family Comprehensive Cancer Center, Membership/Education/Training Program Mentee, 2022
- UCI Health Nursing Excellence, Friend of Nursing, 2024
- UC Irvine The Institute for Meaningful Engagement (TIME) Champion, 2022-2024
Areas of Expertise
- Hematologic Malignancy Clinical Pharmacy
- Hematopoietic Stem Cell Transplantation
- Acute Leukemia Pharmacotherapy
- Lymphoma Treatment Optimization
- CAR T-Cell Therapy Management
- Hispanic Oncology Health Disparities
- Oncology Pharmacist Workforce Practice
Recent Publications
- Benitez LL, Signorelli J, Adler K, Cimino S, Darling J, Dotson E, Goodner JA, Harris C, McDevitt RL, Rasor B, Schroader BK, Sirek M, Vogel V, Wolff AS, Griffin SP, “Oncology pharmacist survey: Understanding task value and professional satisfaction” (opens in new tab), Journal of Oncology Pharmacy Practice, pp. 10781552261421501, 2026.
- Lee BJ, Griffin SP, Jeyakumar D, Gamayo A, Rezk SA, Naqvi K, “Acute Myeloid Leukemia With Plasmacytoid Differentiating Cutaneous Lesions: A Case of Double Identity or Active Transformation”, EJHaem, vol. 7, no. 1, pp. e70221, 2026.
- Griffin SP, Chang J, Rower JE, Wang KZ, Lee BJ, Doh J, Liu J, Quach A, Sun Y, Chumnumsiriwath P, Ramos-Perez J, Kongtim P, Ciurea SO, “Optimal Pharmacokinetic Sampling Strategy for Melphalan-Based Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation”, Transplant Cell Ther, vol. 32, no. 2, pp. S615-S616, 2026.
- Zahedi A., Ifejeokwu O.V., Griffin S.P., Dean E.A., “Repurposing mitochondrial-targeting drugs for management of ICANS in CAR T-cell therapy: a novel steroid-sparing approach” (opens in new tab), Frontiers in Pharmacology, vol. 17, 2026.
- Lee BJ, Griffin SP, Doh J, Quach A, Sun Y, Chumnumsiriwath P, Ciurea SO, Ramos-Perez J, Bellman P, Jeyakumar D, Kongtim P, Naqvi K, “Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia” (opens in new tab), British Journal of Haematology, vol. 208, pp. 570-578, 2025.
- Zacholski EH, Dierckes J, Hartnett-Quach D, Noda D, Sharps A, White O, Zacholski K, Griffin SP, “Comprehensive Framework for Oncology Pharmacist-Led Parenteral Anticancer Therapy Patient Education: The Opinion of the American College of Clinical Pharmacy Hematology/Oncology Practice and Research Network” (opens in new tab), Jaccp Journal of the American College of Clinical Pharmacy, vol. 8, pp. 1202-1214, 2025.
- Lee BJ, Griffin SP, Doh J, Quach A, Sun Y, Brem EA, Van Etten RA, Nelson EL, Coombs CC, Chan A, “R-DA-EPOCH Versus DA-EPOCH-R: Impact of Chemoimmunotherapy Sequencing on Treatment Outcomes in Patients With Diffuse Large B-Cell Lymphoma” (opens in new tab), Clinical Lymphoma Myeloma and Leukemia, vol. 25, pp. e1014-e1021, 2025.
- Griffin SP, Signorelli J, Raheem F, Adler K, Benitez LL, Cheng RM, Dotson E, Fares M, Ganti BR, Hickey Zacholski E, Lasko AR, Lewallen AB, Lynch AC, Paulic N, Quach D, Vogel V, Yacobucci M, Riebandt G, “Time to complete oncology pharmacist tasks: A joint opinion of the Hematology/Oncology Pharmacy Association and American College of Clinical Pharmacy's Hematology/Oncology Practice and Research Network” (opens in new tab), Journal of Oncology Pharmacy Practice, vol. 32, pp. 1040-1047, 2025.
- Griffin SP, Lee BJ, Chummumsiriwath P, Kim S, Doh J, Jeyakumar D, Ramos-Perez J, Kongtim P, Ciurea S, “Early Initiation of Tacrolimus Prior to Post Transplant Cyclophosphamide in Peripheral Blood Haploidentical Transplantation”, Transplant Cell Ther, vol. 31, no. 2S, pp. S544, 2025.
- Ali HE, Griffin SP, Doh J, Kim MS, “Outcomes of a Pharmacist Managed Post-Hematopoietic Stem Cell Transplantation Immunization Clinic at a Comprehensive Cancer Center”, American Journal of Health-System Pharmacy, vol. 82, no. Supplement_1, pp. S2430, 2025.
- Lee BJ, Griffin SP, Doh J, Ciurea SO, Jeyakumar D, Kongtim P, Naqvi K, “Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience” (opens in new tab), Annals of Hematology, vol. 103, pp. 5395-5403, 2024.
- Wooten A, Wright J, Thakrar T, Barron A, Grove M, Duggal R, Lee BJ, Doh J, Di Tomasso PM, Joe MD, Griffin SP, “Clinical Oncology Pharmacy Technician: Impact of a New Role on Pharmacy and Patient Metrics at a Large Academic Cancer Center” (opens in new tab), JCO Oncology Practice, vol. 20, pp. OP2300582, 2024.
- Lee BJ, Griffin SP, “Treatment-related toxicity disparities in adult Hispanic acute lymphoblastic leukemia patients receiving pegaspargase-based regimens: A multicenter electronic health research network study” (opens in new tab), Hematological Oncology, vol. 42, pp. e3254, 2024.
- Lee BJ, Griffin SP, Doh J, Chan A, Ciurea SO, Jeyakumar D, Fleischman AG, Naqvi K, Pannunzio NR, O'Brien S, Kongtim P, “HyperCVAD versus pegaspargase-containing regimens for Hispanic adults with newly diagnosed B-cell acute lymphoblastic leukemia” (opens in new tab), European Journal of Haematology, vol. 112, no. 3, pp. 392-401, 2024.
- Griffin SP, Signorelli JR, Lasko A, Andrick BJ, Doan D, Hough S, Riebandt G, Harnicar S, “Oncology pharmacy practice in the United States: Results of a comprehensive, nationwide survey” (opens in new tab), Journal of Oncology Pharmacy Practice, vol. 30, no. 2, pp. 332-341, 2024.
- Griffin SP, Lee B, Doh J, Paradyse AR, Jeyakumar D, Arter Z, Nam H, Blodget E, Smith J, Valek A, Vittayawacharin P, Kongtim P, Ciurea SO, “Strategies to Mitigate the Drug-Drug Interaction between Nirmatrelvir/Ritonavir and Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Azole Antifungals: Results of a Case Series” (opens in new tab), Acta Haematologica, vol. 147, pp. 1-7, 2023.
- Griffin SP, Lee BJ, Pannunzio N, Doh J, Chan A, Ciurea S, Jeyakumar D, O'Brien SM, Fleischman AG, Naqvi K, Kongtim P, “Treatment Outcomes in Adults with Newly Diagnosed B-cell Acute Lymphoblastic Leukemia: A Comparison between Pediatric-Inspired Regimens and HyperCVAD at a Hispanic-Serving Cancer Center”, J Clin Oncol, vol. 41, no. S16, pp. 7048-7048, 2023.
- Lee BJ, Griffin SP, Doh J, Chan A, O'Brien S, Jeyakumar D, Ciurea SO, Becker PS, Kongtim P, “CD19-directed immunotherapy use in KMT2A-rearranged acute leukemia: A case report and literature review of increased lymphoid to myeloid lineage switch” (opens in new tab), American Journal of Hematology, vol. 97, no. 12, pp. E439-E443, 2022.
Contact Information
Email: shawn.griffin@uci.edu
Phone: (949) 824-8009
Address: 286 Berk Hall
Return to topThis profile was created with the help of AI.
Last updated on 9/14/2026.